Cargando…
Colorectal Cancer Biomarkers in the Era of Personalized Medicine
The 5-year survival probability for patients with metastatic colorectal cancer has not drastically changed over the last several years, nor has the backbone chemotherapy in first-line disease. Nevertheless, newer targeted therapies and immunotherapies have been approved primarily in the refractory s...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
MDPI
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6463111/ https://www.ncbi.nlm.nih.gov/pubmed/30646508 http://dx.doi.org/10.3390/jpm9010003 |